NCT04293809View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

January 15, 2020

Study Completion Date

January 29, 2020

Conditions
Breast Augmentation
Interventions
DRUG

Exparel Injectable Product

bupivacaine liposome injectable suspension

DRUG

Bupivacaine Hydrochloride

1.3%, 13.3 mg/mL

Trial Locations (1)

77401

HD Research, Bellaire

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT04293809 - Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation | Biotech Hunter | Biotech Hunter